Stereo- and regioselectivity of hepatic oxidation in man ? Effect of the debrisoquine/sparteine phenotype on bufuralol hydroxylation
- 1 January 1986
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 31 (3) , 313-318
- https://doi.org/10.1007/bf00981130
Abstract
The influence of the debrisoquine/sparteine-type of oxidation polymorphism on plasma bufuralol concentration and the pattern of urine metabolites was studied in extensive and poor metabolizer subjects. (+)- and (−)-bufuralol, and (+)- and (−)-OH-bufuralol in plasma were determined by enantioselective HPLC, and urinary bufuralol and its metabolites were assayed by gas chromatography-mass spectrometry. Three hours after administration of racemic bufuralol the plasma (−)/(+) isomeric ratio for unchanged bufuralol was 1.84 in extensive metabolizers, indicating preferential clearance of the (+)-isomer through aliphatic 1′-hydroxylation and glucuroconjugation, while the (−)-isomer was mainly eliminated by aromatic 4-hydroxylation. Poor metabolizers were characterized by impaired 1′- and 4-hydroxylation, with almost total abolition of the stereoselectivity of these reactions. The data strongly suggest that both 1′- and 4-hydroxylation are catalyzed by the same enzyme. These in vivo observations are in agreement with recent in vitro data obtained in human liver microsomes from phenotyped patients and support the concept of deficiency of a highly stereoselective cytochrome P-450 isozyme as the cause of this polymorphism.Keywords
This publication has 27 references indexed in Scilit:
- The molecular mechanisms of two common polymorphisms of drug oxidation-evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidationXenobiotica, 1986
- The Polymorphic Oxidation of ??-Adrenoceptor AntagonistsClinical Pharmacokinetics, 1986
- Steric configuration and polymorphic oxidation of lipophilic beta-adrenoceptor blocking agents: — correlationsBiochemical Pharmacology, 1985
- Genetic polymorphism in drug oxidation: In vitro studies of human debrisoquine 4-hydroxylase and bufuralol 1′-hydroxylase activitiesBiochemical Pharmacology, 1985
- Characterization of a common genetic defect of cytochrome P-450 function (debrisoquine-sparteine type polymorphism) — Increased michaelis constant (km) and loss of stereoselectivity of bufuralol 1′-hydroxylation in poor metabolizersBiochemical and Biophysical Research Communications, 1984
- Bufuralol metabolism in human liver: a sensitive probe for the debrisoquine‐type polymorphism of drug oxidationEuropean Journal of Clinical Investigation, 1984
- Defective Oxidation of DrugsClinical Pharmacokinetics, 1982
- Determination of bufuralol and its metabolites in plasma by mass fragmentography and by gas chromatography with electron capture detectionJournal of Mass Spectrometry, 1976
- The metabolism of bufuralol: Urinary metabolite profiles in rat, dog and manEuropean Journal of Drug Metabolism and Pharmacokinetics, 1976
- The Influence of Stereochemical Factors on Drug DispositionDrug Metabolism Reviews, 1974